N/A
Completed N=2,448
First Presentation of Parkinson Disease Patients to Neurologist
Source: ClinicalTrials.gov NCT00802178 ↗Enrolled (actual)
2,448
Serious AEs
0.0%
Results posted
Nov 2009
Primary outcomePrimary: Number of De-novo Patients in Whom Monotherapy With Mirapexin® Could be Successfully Initiated — 403; 323; 73; 15 Participants
Summary
In this study information is gathered about the treatment of Parkinson patients who present themselves in a neurological practice for the first time
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of De-novo Patients in Whom Monotherapy With Mirapexin® Could be Successfully Initiated |
403; 323; 73; 15; 19 | — |
| SECONDARY Change From Baseline in UPDRS (Unified Parkinson's Disease Rating Scale) Part I |
-1.20 | — |
| SECONDARY Change From Baseline in UPDRS Part III |
-11.18 | — |
| SECONDARY Global Clinical Assessments of Efficacy of Mirapexin® for All Patients |
1043; 1004; 263; 55; 83 | — |
Eligibility Criteria
Inclusion Criteria
- Parkinson Disease patients presenting to neurologist for first time
Exclusion Criteria
- Hypersensitivity to the active substance or to any of the excipients
Data sourced from ClinicalTrials.gov (NCT00802178). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.